Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 369

1.

Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.

Kojuri J, Mahmoody Y, Zangbar Sabegh B, Jannati M, Mahboodi A, Khalili A.

Cardiovasc Ther. 2010 Jun;28(3):147-52. doi: 10.1111/j.1755-5922.2010.00170.x.

PMID:
20557313
2.

Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.

Salama MM, Morad AR, Saleh MA, Sabri NA, Zaki MM, ElSafady LA.

J Clin Pharm Ther. 2012 Dec;37(6):630-6. doi: 10.1111/j.1365-2710.2009.01083.x. Epub 2009 Aug 12.

PMID:
23121257
3.

High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.

Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF.

Thromb Haemost. 2010 Aug;104(2):279-86. doi: 10.1160/TH10-01-0007. Epub 2010 May 27.

PMID:
20508896
4.

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US.

Circulation. 2007 Jun 26;115(25):3156-64. Epub 2007 Jun 11.

5.

Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management.

Cuisset T, Quilici J, Fugon L, Cohen W, Roux P, Gaborit B, Molines L, Fourcade L, Bonnet JL, Carrieri P.

Arch Cardiovasc Dis. 2011 May;104(5):306-12. doi: 10.1016/j.acvd.2011.03.091. Epub 2011 May 31.

6.

A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.

Wenaweser P, Eshtehardi P, Abrecht L, Zwahlen M, Schmidlin K, Windecker S, Meier B, Haeberli A, Hess OM.

Thromb Haemost. 2010 Sep;104(3):554-62. doi: 10.1160/TH09-11-0765. Epub 2010 Jul 20.

PMID:
20664903
7.

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.

Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators.

Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15.

8.

Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.

Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schömig A, Kastrati A, Sibbing D.

Thromb Haemost. 2010 Dec;104(6):1193-200. doi: 10.1160/TH10-05-0266. Epub 2010 Sep 13.

PMID:
20838744
9.

Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.

Legrand V, Cuisset T, Chenu P, Vrolix M, Martinez C, Dens J, Gach O, Boland J, Claeys MJ, Magne J, Barbato E, Wijns W.

EuroIntervention. 2014 Jun;10(2):204-11. doi: 10.4244/EIJV10I2A34.

10.

Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.

Gao P, Xiong H, Zheng Z, Li L, Gao R, Hu SS.

Platelets. 2010;21(3):183-90. doi: 10.3109/09537101003592700.

PMID:
20201634
11.

How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.

Neubauer H, Lask S, Engelhardt A, Mügge A.

Thromb Haemost. 2008 Feb;99(2):357-62. doi: 10.1160/TH07-10-0624.

PMID:
18278186
12.

Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.

Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Manzo Silberman S, Logeart D, Drouet L, Henry P.

Am Heart J. 2012 Oct;164(4):600-606.e1. doi: 10.1016/j.ahj.2012.06.008.

PMID:
23067920
13.

Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.

Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, Guzman LA, Hernández-Antolin R, Zenni MZ, Macaya C, Fernandez-Ortiz A, Bass TA.

Thromb Haemost. 2008 Jan;99(1):161-8. doi: 10.1160/TH07-09-0562.

PMID:
18217149
14.

Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets.

Würtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD.

JACC Cardiovasc Interv. 2010 Aug;3(8):828-35. doi: 10.1016/j.jcin.2010.05.014.

15.

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.

Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schömig A, von Beckerath N, Kastrati A.

J Thromb Haemost. 2010 Feb;8(2):250-6. doi: 10.1111/j.1538-7836.2009.03709.x. Epub 2009 Nov 28.

16.

Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.

Gurbel PA, Bliden KP, Antonino MJ, Gesheff T, Cummings CC, Dubois BV, Herzog WR, Tantry US.

Thromb Res. 2012 Jan;129(1):1-2. doi: 10.1016/j.thromres.2011.07.048. Epub 2011 Aug 20. No abstract available.

PMID:
21862113
17.

Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.

Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):381-91. doi: 10.1161/CIRCINTERVENTIONS.111.967463. Epub 2012 May 22.

18.

Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.

Li J, Jian Z, Huang L, Guo H, Huang J, Qian D, Fu W, Li A, Song Y.

Biomed Pharmacother. 2009 Sep;63(8):608-12. doi: 10.1016/j.biopha.2008.10.004. Epub 2008 Oct 31.

PMID:
19019624
19.

Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.

Christiaens L, Ragot S, Mergy J, Allal J, Macchi L.

Blood Coagul Fibrinolysis. 2008 Apr;19(3):235-9. doi: 10.1097/MBC.0b013e3282f9ade8.

PMID:
18388505
20.

High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.

Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, Bali L, Lambert M, Alessi MC, Bonnet JL.

Thromb Haemost. 2007 Feb;97(2):282-7.

PMID:
17264958

Supplemental Content

Support Center